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ABSTRACT
Dysregulation of Nuclear Factor Kappa B Activity and Osteopontin 
Expression in Chemically-Induced Atherogenesis.
(December 2003)
Edward Spencer Williams, B.A., Texas A&M University
Chair of Advisory Committee:  Dr. Kenneth Ramos
NF-κB activity is critical in the regulation of atherosclerotic vascular smooth
muscle cell (vSMC) phenotypes induced following oxidative injury by allylamine.  The
present studies were designed to detail dysregulation of NF-κB activity in these altered
phenotypes, and to assess the importance of NF-κB in the regulation of osteopontin, a
cytokine which modulates atherosclerosis.  Increased degradation of IκBα was observed
in allylamine-induced atherosclerotic vSMC phenotypes (henceforth referred to as
allylamine cells).  Enhanced phosphorylation of I-κ-kinases was observed by Western
immunoblotting.  NF-κB DNA binding activity as assessed by electrophoretic mobility
shift assay demonstrated changes in the kinetics and magnitude of induction of binding.
Enhancement of NF-κB binding activity was evident in allylamine cells compared to
controls when seeded on plastic, fibronectin, and laminin, but not collagen I.  Post-
transcriptional alterations in Rel protein expression and nuclear localization partly
account for changes in NF-κB DNA binding activity.  Promoter-specific NF-κB binding
profiles suggest altered dimer prevalence as a consequence of the changes in Rel protein
expression.  The expression of NF-κB regulated genes osteopontin and MMP-2 was
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enhanced in allylamine-treated aortas, while cyclin D1 and MMP-9 were unchanged.  As
the importance of osteopontin in atherosclerosis has been described in several models,
subsequent studies were designed to assess osteopontin promoter activity.  Activity of the
osteopontin promoter was significantly reduced in allylamine cells compared to controls
as assessed using a luciferase reporter.  Deletion analysis suggested the presence of
inhibitory cis-acting elements in the regulatory region of the gene.  Mutation of these
elements, including VDRE, AP-1, NF-κB, and USF1, indicated that NF-κB and USF1
mediate suppression of osteopontin promoter activity in allylamine cells.  Decreased
serine phosphorylation of immunoprecipitated RelA/p65 was observed in allylamine
cells, indicating decreased ability of this protein to transactive gene promoters.  NF-κB
was found to play a role in suppression of osteopontin promoter activity by collagen I-
mediated integrin signaling.  These findings suggest that enhancements in NF-κB activity
suppress osteopontin promoter activity in oxidant-activated vSMC cultures.
Dysregulation of NF-κB activity occurs as a result of altered matrix and intracellular
signaling upstream of the nucleus and possibly differential dimer assembly leading to
cell-specific profiles of NF-κB-dependent gene regulation.
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1INTRODUCTION
According to the World Health Organization (WHO), cardiovascular diseases are
responsible for one third of all deaths in the world, over 16 million per year.  By 2025,
this number is expected to reach 25 million (1).  In the United States, cardiovascular
disease is listed as the cause in over 60% of deaths, more than the next five leading
causes combined (cancer, chronic respiratory diseases, accidents, diabetes, and
influenza/pneumonia).  Medicare costs alone for cardiovascular disease were estimated
at $26.3 billion in 1999 (2). 
Atherosclerosis
Atherosclerosis is a disease in which large- to medium-sized arteries develop a
lesion that can occlude the lumen, blocking blood flow, or rupture, resulting in a
thrombus.  Either of these outcomes can result in myocardial infarction, as well as
cerebral and renal damage.  Occlusion of the lumen by atherosclerosis can also cause
gangrene of the extremities (3).
 
Fatty Streak
Many hypotheses about the onset of atherosclerosis center on the importance of
oxidation of LDL in the vessel wall.  For many years, the prevailing hypotheses have 
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2included a vital role for cholesterol in the onset of atherosclerosis (4).
There are several different types of lipoprotein particles.  In order of increasing
density, there are chylomicrons, very low-density lipoproteins (VLDL), intermediate-
density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density
lipoproteins (HDL).  Each of these families of lipoproteins contain a specific subset of
the nine basic apolipoproteins.  These lipoprotein particles are synthesized in the liver,
and then are distributed to various parts of the body through the blood.  HDL is
responsible for removing cholesterol from peripheral tissues and returning it to the body
(5).  
Generally, lesions form at sites where fatty deposits have accumulated on the
wall of the vessel.  These so-called “fatty streaks” result in concentration-dependent
accumulation of low-density lipoproteins (LDL) in the vessel walls (6).  LDL associates
with the extracellular matrix in the intimal and medial layers. Oxidative modification of
the LDL particles occurs either as a result of interaction with oxidative wastes of cells
within the tissue, or the action of macrophages participating in an ongoing inflammatory
response (7).  
Increases in modified LDL levels in the wall serve to amplify the inflammatory
response.  The earliest stages of this response are characterized by altered expression of
VCAM-1 and ICAM-1, which in turn facilitates migration of leukocytes through the
endothelial layer into the intimal and medial layers.  Furthermore, oxidized lipids induce
transcription of MCP-1 (monocyte chemotactic protein) and M-CSF (macrophage
3colony stimulating factor) (6, 8, 9).  These actions may cause greater oxidation of LDL
that begins and exacerbates the cycle of inflammation at this site.  
Inflammation
Atherosclerosis is a disease of chronic inflammation.  It is generally accepted that
a prolonged inflammatory response at the vessel wall produces an environment
conducive to vascular smooth muscle cell proliferation.  
Many studies and hypotheses suggest that the inflammatory response occurs as a
result of oxidative modification of LDL within the vessel wall (7).  Indeed, oxidized
LDL (oxLDL) is capable of upregulating several inflammatory molecules.  oxLDL is
also chemotactic for monocytes (10).  The oxidation of LDL (the lipids as well as the
proteins) results in a shift to recognition by the scavenger receptors of infiltrating
macrophages (6).  Thus, macrophages phagocytize the oxLDL in large quantities to
become foam cells.
Some evidence suggests that a pre-existing inflammatory condition promotes
deposition of LDL in the vessel.  For example, some inflammatory cytokines including
tumor necrosis factor alpha (TNF-α), interleukin 1 (IL-1), and M-CSF increase binding
of LDL to endothelium (11).  Further, mouse models which do not express MCP-1 or its
receptor display reduced deposition of lipids in the aorta (12).
Whether lipid accumulation or another stimulus initiates the inflammatory
response, the development of pathogenic lesions depends on inflammation.  Disruption
of macrophage function by knocking out MCP-1, M-CSF, or osteopontin attenuate
4lesion formation (13).  The infiltration of monocytes and T lymphocytes starts a cycle of
immune cell recruitment that promotes proliferation of vascular smooth muscle cells,
setting the stage for development of a complex lesion.  
The upregulation of P-selectin is critical in initiation of an immune response to
the inner surfaces of the vessel, as it supports monocyte rolling, and is only expressed in
preatherogenic and atherosclerotic lesions (14).  As noted above, the sudden appearance
of vascular cell adhesion molecule (VCAM-1) and intracellular adhesion molecule
(ICAM-1) on endothelial cells are important for the infiltration of immune cells through
the intima and into the medial wall (3, 8).  MCP-1 (monocyte chemotactic protein 1) is
expressed by vSMCs, attracting monocytes into the tissue (8).  Once they have infiltrated
the tissue, macrophage colony stimulating factor (M-CSF) stimulates differentiation of
monocytes into macrophages.  These differentiated macrophages continue the cycle of
inflammation by secreting more cytokines, including MCP-1, M-CSF, TNFα, TGF-β,
and interleukins (14).  Macrophages also secrete matrix metalloproteinases (MMPs),
which are vital to their ability to migrate through the tissue (15).  The action of MMPs
begins extensive remodeling of the extracellular matrix within the vessel wall.  Lastly,
the macrophages can secrete growth factors including PDGF and IGF-1 that stimulate
the proliferation of vSMCs (14, 16-18).  
Endothelial Injury
Some findings suggest that dysfunction of the endothelial layer is a primary
contributor to atherogenesis, perhaps as a function of increased susceptibility to LDL
5deposition (11).  Causes of endothelial dysfunction include oxidative stress as a result of
hypertension, smoking, high plasma homocysteine concentrations, and diabetes.  
Matrix Remodeling
The extracellular matrix of the vessel wall plays a critical role in maintaining its
structural integrity, but perhaps more importantly, signaling of normal matrix through
cell surface receptors such as integrins helps maintain function and differentiation status
of endothelial cells and vascular smooth muscle cells (vSMCs) (11).  Thus, the intense
matrix remodeling that occurs in atherosclerotic progression plays two pathological
roles: decreased ability of the vessel to maintain its function in blood flow and pressure,
and also release of vSMCs and endothelial cells from inhibitory mechanisms that check
proliferation.
There are several classes of proteases that participate in degradation of matrix
proteins of the vessel wall during atherosclerotic progression.  These include
metalloproteinases MMP-1 (collagenase), MMP-2 (gelatinase A), MMP-3 (stromelysin),
MMP-9 (gelatinase B), and MMP-12 (metalloelastase) (19) in human atherosclerotic
plaques as well as in rabbit models, as well as cathepsins S and K (14).
Matrix metalloproteinases are members of a family of secreted enzymes that
degrade ECM components.  The activity of these enzymes is regulated at multiple levels,
including transcription and protein synthesis of inactive zymogens, enzymatic activation,
and interaction of the activated MMP with natural inhibitors, tissue inhibitors of
metalloproteinase (TIMPs) (20, 21).  vSMCs constitutively produce MMP-2, TIMP-1
6and TIMP-2 (22, 23).  In atherosclerotic lesions, a major source of metalloproteinases
appears to be the infiltrating macrophages, which secrete metalloproteinases and
cytokines that stimulate the vascular smooth muscle cell layer to produce more and a
wider range of MMPs (24,2 5).
Subsequent to these degradative processes, there are striking changes in the
composition of the extracellular matrix.  Basement membrane components, generally
regarded to be quiescent in regard to vSMCs, are downregulated (eg fibrillar collagen,
and laminin), while interstitial proteins, including monomeric collagen I, elastin, and
fibronectin, increase in predominance (26).
Type I and III fibrillar collagens are major components of the ECM in normal
vessels (27).  However, in atherosclerotic vessels, monomeric collagen I predominates
(28). The abundance of precursor collagen I rather than polymerized collagen may be
important in allowing cells to proliferate (29). Several studies have shown a role for
fibrillar collagen in vSMC quiescence, possibly through enhanced expression of cyclin-
dependent kinase inhibitors (30, 31). Monomeric collagen I, a major component of the
remodeled matrix, is unable to arrest the growth of vascular smooth muscle cells (32).
Thus, through degradation of mature collagens, and production of collagen monomers,
vascular smooth muscle cells are released from an inhibitory mechanism.  However, the
presence of monomeric collagen in the injured vessel wall plays a role in activation of
infiltrating macrophages, causing upregulation of MMP-9 and CD71 (33).  
Early after balloon injury, the heparan sulfate and chondroitin sulfate
proteoglycans are disrupted.  Altered SMCs start to produce chondroitin sulfate anew,
7but it is not quiescent for SMCs (34).  Heparan sulfate proteoglycans can inhibit vSMC
proliferation by interfering with PKC-mediated transcription factor activation (29).
Thus, these matrix constituents may be critical to maintenance of SMC contractile
phenotype. 
Another protein that helps maintain SMC in their contractile state is laminin, a
component of the intimal basement membrane (35).  Some findings suggest that
disruption of the basal lamina is vital to vSMC activation.  Indeed, laminin disappears in
atherosclerotic regions, specifically around vSMCs that have shifted to a more
proliferative phenotype (26).
Fibronectin is a matrix protein that promotes vSMC proliferation (36).  This
protein is not present in healthy vessels, but appears rapidly after vessel injury (26).  Not
only does fibronectin promote vSMC dedifferentiation and proliferation, but subsequent
to deposition, it may polymerize into fibers that provide tracks for vSMC migration into
the intima (37).
Osteopontin is regarded as a key molecular target of injury within the vascular
wall, as a result of its appearance in atherosclerotic plaques.  Originally, this protein was
described as a critical regulator of bone remodeling; later, it was described as a cytokine
capable of modulating the action of inflammatory cells (38).  For example, osteopontin
plays a role in macrophage functions, including differentiation, migration, adhesion, and
cytokine release (39).
Osteopontin has been the focus of many studies in recent years due to its
dramatic elevation in atherosclerotic lesions, though it does not appear in normal vessels
8(40).  Several studies indicate that osteopontin plays a key role in plaque progression;
antibody-mediated blockade inhibited intimal thickening in a rat model (41).
Subsequent to production, osteopontin is sequestered in the extracellular matrix.  There,
it binds to integrin receptors αVβ1, αVβ3, αVβ5 and α9β1 on vSMCs (41, 42).  Through
binding to these receptors, osteopontin can modulate several functions of vSMCs
including proliferation, migration, and expression of inflammatory cytokines through
activation of the transcription factor nuclear factor kappa B (NF-κB) (43).  
Vascular Smooth Muscle Cell Phenotypic Modulation
Mature vascular smooth muscle cells maintain the tone of large blood vessels
thanks to a highly developed contractile apparatus, which consists of smooth muscle
myosin and actin isoforms, and anchoring proteins such as vinculin, metavincunlin, α-
actinin, and talin (44).  Specific components of the contractile machinery are useful as
markers of SMC identity, including SM22α, SM-myosin heavy chains, SM α-actin,
calponin, and β-tropomyosin to name a few (45, 46).  
Many investigators focus on vascular smooth muscle cell activation as the critical
step in atherogenesis.  Fully differentiated vSMCs exhibit minimal proliferation or cell
death (47).  Following injury, a phenotypic shift occurs, allowing migration and
proliferation to begin.  This shift leads to changes in intra- and extracellular protein
expression (29). Phenotypic modulation of vSMCs occurs in various physiologic
processes, including fetal and post-natal development, regeneration and repair of blood
vessels, and myometrial development during pregnancy (48).
9vSMC dedifferentiation is signaled by a loss of expression of contractile proteins
(49).  The expression of these SMC-specific proteins appears to be under the control of
serum response factor (SRF) (50, 51) .  This transcription factor regulates transcription
via binding to a CarG element, which is present in the promoter of all the putative SMC
marker genes.  The ability of SRF to effect transcriptional activation of these smooth
muscle-specific promoters is dependent on a number of signaling pathways, including
interactions with a number of other proteins, including Nkx3.2, GATA-6 (52), and a
member of the ternary complex factor (TCF) family of proteins, which is activated by
MAPK-dependent phosphorylation d(53).  This relationship may account for a recent
finding that Akt-mediated Raf inhibition can also inhibit the expression of smooth
muscle marker proteins (54).  Also, the ability of SRF and its partner proteins to bind a
CArG element on smooth muscle-specific promoters may rely on hyperacetylation of
these regions, a phenomenon which only occurs in differentiated SMCs (55).  Lastly,
recent studies have demonstrated that SRF-dependent expression of smooth muscle
markers is dependent on RhoA-mediated actin polymerization, suggesting an intricate
relationship between the status of contractile machinery of vSMCs and the expression of
its components (56).  
Dedifferentiation of vSMCs is accompanied by expression and increased activity
of NAD(P)H oxidase (57). This enzyme is comprised of 5 subunits: gp91phox, p22phox,
p47phox, p67phox, and Rac (58).  The activity of this oxidase has been implicated in
increased vSMC proliferation in vitro (58), and in SMC hyperplasia following bypass
graft (57).  
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Features of the altered SMCs in atherosclerosis include morphologic changes
(49), altered secretion and deposition of extracellular matrix (26, 27, 34),
hyperproliferation (59), and an accompanying panoply of changes in intracellular
signaling (60) .  A number of studies have suggested chromosomal alterations or
mutations in cells isolated from atherosclerotic lesions (61-64), but no specific mutation
has been inplicated in atherogenesis.
Morphologic changes – As mentioned above, phenotypic modulation of vSMCs during
atherogenesis leads to a distinct morphological change.  The loss of smooth muscle-
specific contractile proteins and the reorganization of the remaining structure have been
detailed in several studies (47, 49).   Differentiated vSMCs are known as “contractile”,
and injured vSMCs are termed “synthetic”, due to increased visibility of the nucleolus
and more extensive endoplasmic reticulum (ER).  These synthetic phenotypes also
appear more rounded in culture, while contractile vSMCs are more elongated and
spindle-shaped (44).
  
Matrix signaling – The extensive remodeling of vascular ECM during atherosclerosis
leads to a variety of changes in cell behavior as a result of matrix-related signaling.
Degradation of interstitial fibrillar collagens and basal lamina component laminins
effectively release vSMCs from stimuli that help maintain them in a differentiated
phenotype (65, 66).  Although the synthetic vSMCs begin to synthesize collagen I, the
monomeric form is unable to effect the same regulation of phenotype as the mature form
11
(29).  Further, the buildup of collagen I can effectively isolate vSMCs from cell-cell
contracts, which can contribute to a loss of contractile phenotype (28).  
Hyperproliferation  - Deregulated proliferation of vSMCs is thought to be a critical event
in the development of atherosclerotic lesions (67).  Changes in the medial milieu both
expose vSMCs to growth stimuli and release them from inhibitory influences.  As a
result, proliferating vSMCs and the accompanying increase in ECM deposition cause
thickening of the media.  vSMCs that migrate into the intima also cause neointimal
thickening (29). 
Several studies have verified that atherosclerotic hyperplasia of SMCs occurs
through clonal expansion, either of a single altered cell (68), or of a population of clonal
cells in lesion-prone areas (69).
There are a large cadre of signaling pathways that contribute to vascular smooth
muscle cell growth and proliferation.  Some of these are detailed in Fig. 1.  Binding of
growth factors to their cognate receptors, as well as attachment of integrin receptors to
ECM ligands, cause activation of ras, PI-3-kinase (70), and phospholipases.  Three
growth factors in particular receive most of the attention as promoters of vSMC
phenotypic modulation: PDGF, EGF, and IGF (67).  The activities of signaling
intermediates downstream of these growth factors branch out through a cellular network
of signaling molecules; the combined actions of these proteins activate proteins in the
mitogen-activated protein kinase (MAPK) family (71, 72).
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Fig. 1:  Pathways of growth and proliferation of vSMCs.  A cornucopia of signaling
pathways interact to effect regulation of vSMCs growth and proliferation, including
phospholipase C (PLC), growth factor receptor binding, integrin binding, ras/raf/mitogen
activated protein kinase (MAPK), protein kinase C (PKC), phosphotidyl inositol 3
kinase (PI3K), IκB-kinases (IKK).  These pathways converge at two transcription
factors, AP-1 and NF-κB, which regulate expression of many genes related to growth
and proliferation.
The MAPK family includes serine/threonine kinases ERK 1 and 2, which
regulate growth and differentiation, c-Jun N-terminal kinase (JNK), and p38 MAPK.
The latter two kinases play roles in stress responses, specifically apoptosis and
inflammation.  Though many different signals feed into MAPK cascades, specificity of
signal to response may be maintained by a set of so-called scaffolding proteins
(reviewed in 73, 74).  Two of the specific targets of the MAPK pathways include
constituents of the transcription factors AP-1 and NF-κB.
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Activating protein 1 (AP-1) is a dimeric transcription factor.  It is composed of a
combination of proteins from the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-
2), Maf (c-Maf, MafB, MafA, MafG, Nr1), and ATF (ATF2, ATF3, B-ATF, JDP1,
JDP2) families.  Each of these proteins are substrates for MAP kinases, and thus after
JNK and ERK are activated, they translocate to the nucleus and phosphorylate the AP-1
constituent proteins (75).  These proteins then dimerize and bind to the promoters of
genes with roles in proliferation, inflammation, and matrix protein genes.  AP-1 can bind
to two elements, the TPA response element (5’-TGAG/CTCA-3’) and the cAMP
response element (5’-TGACGTCA-3’).  
The importance of AP-1 in vSMC proliferation following balloon injury was
recently demonstrated using decoy oligonucleotides for AP-1 binding (76).  Also, AP-1
is activated in vSMCs in response to MCP-1 and IL-1, which suggests potential
activation in response to the inflammatory cascade in the vessel wall (77).
NF-κB is a dimeric transcription factor first described in B cell activation.
However, this transcription factor has been observed ubiquitously in mammalian cells.
Its targets include growth genes (cyclin D1, cyclin D3), inflammatory genes
(interleukins, TNFα, MCP-1), cell adhesion molecules (ICAM-1, VCAM-1), stress
response genes (angiotensin II, iNOS, COX-2), apoptosis genes (Bcl-xl, Fas ligand,
IAPs), growth factors (PDGF, M-CSF), and enzymes (matrix metalloproteinases,
xanthine oxidase) (reviewed in 78).  The DNA binding site for NF-κB is 5’ – 
GGRRNNYYCC –3’, where R represents any purine base, Y any pyrimidine, and N any
base (79).
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NF-κB is comprised of almost any hetero- or homodimer of Rel proteins, which
include p50, p52, p65/RelA, RelB, and c-Rel.  These proteins consist of two primary
domains: a Rel homology domain (RHD), which contains the regions responsible for
DNA binding, nuclear localization, and protein dimerization, and a transactivation
domain (Fig. 2).  However, neither p50 nor p52 contain a potent transactivation domain
(80).
Each dimer has varying specificity for NF-κB binding domains (reviewed in 79).
Fig. 2: A schematic representation of the Rel proteins, the constituents of NF-κB.
There are five members of this family, including Rel A/p65, c-Rel, RelB, p50, and p52.
All of these proteins possess a Rel-homology domain, which contains the protein
dimerization and DNA-binding domains.  p65, c-Rel, and RelB also contain potent
transactivation domains, which are lacking in p50 and p52.  NF-κB dimers bind to the
depicted generalized DNA sequence and regulate gene expression.
.
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Recently, Nijnik et al. examined the binding specificity of p50 and p52 to a wide
variety of NF-κB binding sequences, using principal coordinate analysis to predict
binding affinity of these proteins for all possible NF-κB DNA-binding sequences (81).
The result of varied affinity of NF-κB dimers for binding domains is regulation of a
subset of genes that possess specific sequences.  Differential dimer binding specificity
plays two complementary roles in gene expression: 1) different external stimuli may lead
to activation of different dimers (82), and 2) polymorphisms in promoter regions may
cause altered differential binding of NF-κB and thus transcriptional activation (83).
Examinations of this phenomenon have barely scratched the surface, and it appears
certain that this level of regulation will become a critical point of study in coming years.
The NF-κB dimer is typically sequestered in the cytoplasm, through its
association with a protein inhibitor of κB activity, IκB.  Binding of IκB masks the
nuclear localization sequence of the Rel protein dimer (84, 85).  
The critical point of regulation for NF-κB activation is accomplished by
phosphorylation of the IκB by an IκB-kinase (IKK) complex.  Following
phosphorylation, the IκB is polyubiquitinated by E3 ligase, which targets it for
degradation by the 26S proteosome.  After the IκB is degraded, the nuclear localization
sequence on the NF-κB dimer is exposed, allowing nuclear translocation and subsequent
binding to DNA (Fig. 3) (86).
There are several varieties of IκB, including IκBα, IκBβ, IκBε, and Bcl-3. p50
and p52 are generated by processing of precursor proteins p105 and p110, respectively. 
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Before processing, these proteins contain IκB-like domains. Each IκB may play a role in
different pathways (87).  IκBα is the strongest inhibitor of NF-κB translocation and is
rapidly degraded in response to several stimuli, while IκBβ and IκBε are degraded with
slower kinetics (88).  IκBα is degraded in response to IL-1, LPS and TNFα, while IκBβ
is degraded in response to IL-1 and LPS, but not TNF-α (89).
Fig. 3:  A schematic representation of NF-κB activation. An NF-κB dimer, typically
composed of p50 and p65, is sequestered in the cytosol via masking of the nuclear
localization sequence by IκB.  The IKK complex binds the IκB and serine
phosphorylates it, which targets it for polyubiquitination and degradation.  The free
dimer then translocates to the nucleus where it is free to bind to DNA.
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The IKK complex consists of two kinase subunits (IKK1/α and IKK2/β), and a
regulatory subunit (IKKγ or NEMO) that facilitates regulation of kinase activity via
interactions with upstream signaling molecules.  A variety of upstream signaling
cascades funnel into NF-κB activation, including PKC (90), ras (91), NIK (92) and
MEKK1 (MAPK kinases) (93), and PI3K/Akt (94, 95).  Once activated, the IKK
complex performs multiple roles in NF-κB activation, the best studied of which is
phosphorylation of IκB.  Recent studies indicate that IKK2/β is responsible for this
activity, while IKK1/α may be responsible for phosphorylation of the Rel proteins
themselves.  This phosphorylation event apparently plays a role in the ability of the NF-
κB dimer to transactivate promoters and thus promote transcription of target genes,
thanks to association with chromatin remodeling factors including CBP/p300 (96) and
HDAC (97).  
Several reports have indicated that NF-κB activity plays a critical role in
proliferation (98, 99), especially in vascular smooth muscle cells (100).    
Risk factors
The American Heart Association has identified a number of risk factors for the
development of atherosclerosis.  Not surprisingly, most of them are inter-related.  Many
of them share a common endpoint: the generation of reactive oxidative species within
the vessel, which suggests that oxidative stress is a crucial step in atherogenesis (101).
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Hypercholesterolemia - Familial hypercholesterolemia (FH) is an inherited disorder
characterized by high levels of blood cholesterol.  Homozygous defects in LDL receptor
usually result in atherosclerosis, which causes heart attacks at a young age.  Normally,
the LDL receptor is localized to a specialized region of the plasma membrane, known as 
a clathrin-coated pit.  Normally, an LDL particle, a composite of proteins, fatty acids,
and cholesterol esters, is internalized by LDL receptor-mediated endocytosis.  However,
in cases of high concentrations of cholesterol in blood, a concentration-dependent
accumulation of cholesterol in the vessel wall can occur.  Deposition of these lipid
particles is quickly followed by oxidation, and an inflammatory response conducive to
the formation of atherosclerotic lesions (4, 102, 103).  
The sequence of events in this process is still a matter of debate; injury to the
vessel wall as a result of shear stress or chemical injury and a subsequent inflammatory
response may make the vessel wall more permeable to lipid particles (104).  Several
critical examinations of epidemiological and experimental evidence call into question
the importance of cholesterol in atherosclerosis and cardiovascular diseases (reviewed in
(105, 106).  These reviews suggest that in most animal models, including non-human
primates, extremely high doses are required to induce atherosclerosis.  Also, thorough
analysis of epidemiological data suggests a failure to demonstrate conclusively a
correlation between dietary cholesterol and atherosclerosis.    However, a role for
oxidation of LDL in atherosclerotic plaque progression has a lot of experimental support
(For a review, see 6, 10, 107).
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High fat diet/obesity  - Several studies have shown relationships between obesity and
higher levels of serum cholesterol.  Aside from the increased risk conferred by
hypercholesterolemia, adipose tissue can secrete an array of inflammatory cytokines
including TNF-α, IL-6 and angiotensinogen (13).  These adipokines create a
proinflammatory milieu which favors the development of atherosclerotic lesions.  Also,
high TNF-α can cause insulin resistance, setting up a diabetic condition.  Thus obesity
converges with three other risk factors: diabetes, hypercholesterolemia, and
hypertension.  
Hypertension - Angiotensin II is often elevated in patients with hypertension.  This
cytokine is known to stimulate growth of smooth muscle cells (via activation of PLC),
and increase steady-state levels of hydrogen peroxide, superoxide, and hydroxyl radicals
in plasma (11).  The increases in ROS may occur subsequent to AngII-mediated
induction of NADPH oxidase expression and activity. (108)  Also, AngII enhances
osteopontin expression in kidney (109).
Homocysteine  - Autopsy results have suggested that defects in metabolic pathways for
homocysteine degradation coincide with advanced atherosclerosis.  Common defects
include cystathionine β-synthase and methylenetetrahydrofolate reducatase.
Homocysteine is toxic to endothelium, increases collagen production in vSMCs, and
decreases the levels of nitric oxide, which plays a role in protecting the vessel wall from
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atherogenesis.  (11).  Serum homocysteine is also elevated in patients suffering from
hypertension, suggesting a link between these two risk factors (110).
Shear stress - “Oscillations” in blood flow have been described in regions where
atherosclerotic lesions develop (111).  Disturbances in flow can alter expression of
critical genes involved in atherosclerosis, including PDGF and ICAM-1.  Also, at sites
of altered blood flow, eNOS expression is reduced, thus lowering the levels of NO,
which is both antiatherogenic and vasodilatory (14).  Further, these stresses stimulate
superoxide production in endothelial cells, and a concomitant decrease in glutathione
levels (108)  
Diabetes mellitus - Diabetes is a disease of impaired glucose utilization. Metabolic
alteration in diabetes is associated with increased formation of glucose-derived
aldehydes, leading to advanced glycation endproducts (AGEs), and methylglyoxal.
Protein adduction of these metabolites in blood vessels results in compromised
vasomotor function.  Further, nonenzymatic glycation reactions can contribute to
oxidative stress (112). Increased glycation of collagen (nonenzymatic, would occur more
in diabetes) can enhance entrapment of LDL (65).
Some evidence suggests a role for a circulating form of a vascular-specific
enzyme semicarbazide-sensitive amine oxidase (SSAO), which may be secreted by
vascular cells. This enzyme is responsible for converting aminoacetone to
methylglyoxal, a substance connected with vascular damage.  The blood concentration
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of methylglyoxal is increased in diabetes, with a strong correlation between levels and
degree of diabetic complications (113).  
High blood glucose may also directly cause increased proliferation of vascular
smooth muscle cells through the induction of NAD(P)H oxidase and subsequent
production of superoxide (58). 
Smoking - The American Heart Association estimates that 150,000 deaths per year from
cardiovascular disease are related to smoking (2).  Smoking initiates, aggravates, and/or
accelerates lesion formation (114)  Several molecular mechanisms have been proposed
behind this phenomenon.  Nicotine can stimulate DNA synthesis in arterial smooth
muscle cells in vitro (115), as well as dedifferentiation of vSMCs (116).  Carbon
monoxide (CO) from smoke may directly damage endothelial cells or increase cell
permeability.  Benzo[a]pyrene (BaP), a polycyclic aromatic hydrocarbon that is a
component of cigarette smoke, can cause lesion formation in animal models.  Both BaP
and CO cause oxidative injury in vessel tissues (117-119). 
Experimental Models
Diet
Diet-induced atherosclerosis as an experimental model was born after the study
of Ignatowski in 1908 showed intimal thickening in rabbits fed a diet of animal tissues
including meat, eggs, and milk (reviewed in 120).  Five years later, other investigators
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demonstrated that lipids were primarily responsible, feeding rabbits with cholesterol
dissolved in vegetable oil (reviewed in 121).
Studies have repeatedly demonstrated that diet-induced hypercholesterolemia is
sufficient to induce atherosclerotic lesions similar to those seen in humans.  This
phenomenon is not observed only in rabbits, but also in mice, hamsters, guinea pigs,
pigeons, quail, chickens, pigs, dogs, cats, and non-human primates (122).  However,
several recent reviews of the experimental evidence suggest that the doses required to
create atherosclerotic lesions are so high that no useful extrapolation could be made to
humans (105, 106).
ApoE Knockouts
Hypercholesterolemia can also be induced genetically, by knocking out critical
genes involved in normal uptake of LDL particles.  In particular, apolipoprotein E
knockout mice have become popular standards for atherosclerosis studies, as they
develop atherosclerosis even on normal mouse diets (123) .  The loss of apoE results in
the generation of fewer HDL particles, generating hypercholesterolemia as a result of the
loss of HDL scavenging cholesterol from peripheral tissues (124).  
Mechanical Injury
Balloon angioplasty is a widely used method in animal models for producing
lesions that mimic atherosclerosis.  This method mimics restenosis, a common problem
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after balloon embolectomy.  Many patients experienced accelerated regrowth of lesions
after treatment by this method (125, 126).  
Hypertension
Hypertension is an important risk factor for development of atherosclerosis.
Thus, many models have focused on generating atherosclerosis by inducing
hypertension.  One early study generated hypertension by suspending animals by their
hind limbs (reviewed in 122).  Fortunately, modern studies use more humane methods,
including infusions of AngII and surgical kidney removal as procedures to generate
artificially hypertensive animals.  Also, several genetically engineered strains of
hypertensive lab animals are commercially available.
Allylamine
Several studies in this laboratory as well as others have demonstrated the
viability of a model of chemical oxidation in vivo which produces atherosclerotic
plaques in laboratory animals.  Allylamine (CH2=CHCH2NH2), a simple monoaliphatic
amine, is an industrial reagent used in the production of vulcanized rubbers,
pharmaceuticals, and polymers.  When allylamine is administered by gavage to Sprague-
Dawley rats, the animals develop aortic lesions reminiscent of those seen in human
atherosclerosis (Fig. 4).  Allylamine is converted to acrolein and hydrogen peroxide in
the vessel wall by semicarbazide-sensitive amine oxidase (SSAO).  
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Early experiments by Boor and Nelson demonstrated “vigorous” acrolein
production in aortic homogenates isolated from rats and humans, a levels six times
higher than other tissues (127).  Conversion of allylamine to acrolein could be inhibited
by semicarbazide.
Semicarbazide-sensitive amine oxidase (SSAO), also referred to as benzylamine
oxidase (BAO) is localized extensively in cardiovascular tissues.  Levels of this enzyme
are increased in the plasma of diabetic patients, as well as those with congestive heart
failure (128). This copper-containing enzyme is responsible for the degradation of amino
Fig. 4: A schematic representation of the allylamine model.  Male Sprague-Dawley
rats are treated for 20 consecutive days with allylamine.  Allylamine accumulates in
vascular tissues, where is is converted to acrolein and hydrogen peroxide by
semicarbazide-sensitive amine oxidase (SSAO).  These two oxidative by-products cause
oxidative stress in the tissue.
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acid by- products.  Some of its potential substrates include dopamine, histamine,
methylamine, and tryptamine (129).  It may be responsible for inactivating toxic amines
that enter the blood through digestion or inhalation (112).  Studies suggest that SSAO is
localized in the plasma membrane, possibly facing outward to metabolize amines in the
extracellular space (129).  The work of Yu and Zuo (130) suggests that circulating
SSAO acts on methylamine to create formaldehyde, which injures endothelium and thus
contributes to atherosclerosis.  Other reports suggest a role for SSAO in the maturation
of collagen or elastin (131), much like its relative lysyl oxidase (LyO) (132, 133).  
In 1990, Boor, Hysmith, and Sanduja identified SSAO as the enzyme responsible
for the conversion of allylamine to acrolein (134).  Enyzmatic activity responsible for
acrolein formation after allylamine exposure resides in the microsomal and
mitochondrial fraction of aortic homogenates (135).  Other by-products of this reaction
include hydrogen peroxide, and ammonia.  
Acrolein is a highly reactive aldehyde that can bind to and disrupt the functions
of proteins and nucleic acids.  The anticancer drug cyclophosphamide is metabolized
into acrolein in vivo (136, 137).  Also, neutrophils produce acrolein at sites of
inflammation by enzymatic conversion of threonine by myeloperoxidase (138).
Microarray analysis suggested that acrolein enhances expression of stress response
genes, including glutathione-S-transferases (GSTs) and γ-glutamyl cysteine synthetases
(γ-GCS) (139).  Acrolein can conjugate with macromolecules by Michael-type addition
(140), and can also promote lipid peroxidation (Fig. 5) (141).  
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Hydrogen peroxide in the intracellular compartment causes oxidative stress by
depleting the pool of available glutathione.  Also, through the Haber-Weiss reaction,
hydrogen peroxide and superoxide can interact to form destructive hydroxyl radicals
(O2
•-  + H2O2 ? O2 + OH- + OH•) (Fig. 6) (139).  Not only can these reactive oxygen
species damage intra- and extracellular macromolecules, they participate in a variety of
physiological signaling pathways, including growth factor-mediated signaling, MAPK
activation, and calcium signaling (142).
Fig. 5:  Metabolism and toxicity of acrolein.  This by-product of allylamine
metabolism causes depletion of glutathione through conjugation, dysfunction of proteins
through adduction, and lipid peroxidation.
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Modulation of Vascular Smooth Muscle Cell Phenotypes by Allylamine
In Vivo
Previous experiments have demonstrated that chronic oxidative injury by allylamine can
induce atherosclerotic lesions in Sprague-Dawley rats.  (143).  Most of these lesions
occur in the descending aorta close to the heart (144). Further experimentation suggested
that a result of allylamine treatment was the generation of oxidative stress and lipid
peroxidation in the vessel wall (145).
Fig. 6:  Metabolism and toxicity of hydrogen peroxide.  This by-product of allylamine
metabolism causes oxidative stress by depleting stores of glutathione and ascorbic acid.
Also, hydrogen peroxide can be metabolized to hydroxyl radicals via the Fenton
reaction.
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In Vitro
When vascular smooth muscle cells are isolated from control and allylamine-
treated animals (hereafter referred to as control and allylamine cells), the allylamine cells
display marked morphologic variations from control cells (146).  As with atherosclerotic
vSMCs, the injured cells appeared more rounded and fibroblast-like in comparison to the
spindle-shaped control cells.  Though the expression of α-actin did not appear to be
altered, the organization of the contractile apparatus was markedly reduced (147).
Allylamine cells also proliferate much more rapidly than control counterparts (146).  The
altered phenotype that arises as a result of allylamine injury is sustained over multiple
rounds of serial passage.
As matrix plays an important role in atherosclerotic disease, ECM deposition and
signaling were the focus of subsequent studies in the Ramos laboratory.  The
proliferative advantage of allylamine cells was manifest only when cells were seeded on
glass, not plastic, suggesting the importance of matrix deposition in the altered
allylamine phenotype.  Further experimentation revealed that a matrix secreted by
allylamine cells increased thymidine incorporation of control cells threefold (147).  Also,
conditioned media from allylamine cells enhances DNA synthesis in control cells more
than 2-fold.  Integrin mediated signaling is critical to these enhancements, as thymidine
incorporation in allylamine cells increases upon treatment with GRGDS peptides.  Some
of the alterations in matrix signaling could rely on alterations in expression of integrin
subunits (148).
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The influence of matrix and RGD-containing peptides is demonstrated by
osteopontin.  Similar to atherosclerotic vSMCs, allylamine cells overexpress
osteopontin, and a 36 kDa fragment thereof.  Several studies indicate that osteopontin
binding to αV integrin receptors is critical to the proliferative advantage of allylamine
cells (148, 149).  Other matrix interactions also influence proliferation in this system.
Collagen I, a quiescent influence on vSMCs, inhibits hyperproliferation of allylamine
cells, but the proliferative advantage is maintained on fibronectin, laminin or plastic. 
The alterations in matrix signaling are reflected in changes in several signaling
pathways within the cell.  These pathways included ras/raf/MAPK, PI3kinase, and PKC.
Allylamine cells exhibit enhanced c-Ha-ras mRNA levels relative to controls (150).  The
activity of PI3kinase is higher in allylamine cells (151).  PKC activity in allylamine-
injured vessels, and cells isolated from injured vessels, is enhanced compared to controls
(152).  Inhibition of PKC by sphingosine and PI3kinase by staurosporine caused a
reduction in allylamine cell proliferation, suggesting a pivotal role for these two
signaling cascades in maintenance of the altered phenotype.
NF-κB DNA binding activity is enhanced in allylamine cells compared to
controls (148).  This finding is consistent with increased activity in several pathways
upstream of IκB phosphorylation by IKK (ie ras/raf/MAPK, PI3K and PKC).  Treatment
with PDTC preferentially inhibited proliferation of allylamine cells, suggesting a vital
role for NF-κB activity in regulation of the oxidant-induced atherogenic vSMC
phenotype.  
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Perturbations in upstream signaling cascades and NF-κB DNA binding activity
suggested a critical role for this transcription factor in phenotypic maintenance in this
oxidant injury model of atherosclerosis.  As the promoter region of osteopontin contains
a binding domain for NF-κB, we hypothesized that NF-κB plays a role in transcriptional
regulation of this cytokine.  Thus, the following aims were addressed:
1) Elucidation of modulated NF-κB activity and its contribution to atherogenic
vSMC phenotypes.  
Assessment of NF-κB activity was performed across a variety of growth
conditions.  Experiments examined both IκB degradation and IKK activation, as well as
the phosphorylation status of p65/Rel A.  The steady-state levels of the Rel proteins
themselves were measured both in the cytosolic and nuclear compartments.  The
importance of matrix signaling in regard to NF-κB was also assessed.  Ultimately, the
contribution of NF-κB activity to the atherogenic phenotype was studied by examining
binding profiles across a variety of promoter targets, and also by measuring RNA levels
of NF-κB-regulated genes.
2) Analysis of the osteopontin promoter sequence and identification of critical
regulatory regions in atherogenic phenotypes.
Using luciferase vectors, osteopontin promoter activity was compared between
control and allylamine cells.  Sequential deletion and site-directed mutagenesis were
used to identify regions of the promoter critical to differential gene regulation.
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MATERIALS AND METHODS
Materials
Allylamine (99% pure) was purchased from Aldrich (Milwaukee, WI).  Medium
199, trypsin, and antibiotic/antimycotic solution were purchased from Gibco (Grand
Island, NY).  [32P]-ATP was purchased from NEN Radiochemicals (Grand Island, NY).
NF-κB consensus oligonucleotide and T4 polynucleotide kinase were purchased from
Promega (Madison, WI).  Antibodies for Rel proteins, IκBα, IκBβ, and IKK were
purchased from Santa Cruz Biotechnologies (Santa Cruz, CA).  The antibody for
phosphoserine was obtained from Zymed Laboratories Inc. (San Francisco, CA).
Protein A-sepharose beads were obtained from Amersham Biosciences (Piscataway, NJ).
Matrix coated plates (BioCoat) were purchased from Becton Dickinson (Franklin Lakes,
NJ).  Nitrocellulose membranes were purchased from BioRad (Hercules, CA).
Supersignal Dura chemiluminescent substrate was purchased from Pierce (Rockford,
IL).  Synthetic oligonucleotides were obtained from Integrated DNA Technologies
(Coralville, IA).  SYBR Green was obtained from Applied Biosystems (Foster City,
CA).  Plasmid and RNA purification kits, and DNase-treatment kits were obtained from
Qiagen (Valencia, CA).  QuikChange Site-Directed Mutagenesis Kit was obtained from
Stratagene (La Jolla, CA).  Fugene 6 and Reverse Transcriptase kits were obtained from
Roche (Indianapolis, IN).  All other chemicals were purchased from Sigma Chemical
Co. (St. Louis, MO).  
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Aortic Isolation and vSMC Culture
Male Sprague-Dawley rats were gavaged with allylamine (70 mg/kg) or tap
water daily for 20 days as previously described (146).  Aortas were isolated, and either
homogenized for RNA isolation or set aside for primary culture.  vSMCs were isolated
by successive enzymic digestion of isolated aortas as previously described (153).
Subcultures were prepared by trypsinization of subconfluent cultures and maintained in
Medium 199 supplemented with 10% FBS and 2 mM L-glutamine in 5% CO2:95% air at
37°C.  Cultures between passage levels 19-25 were used for all experiments.  G0
synchronization was accomplished by incubation of cell cultures for 72 h in Medium 199
containing 0.1% FBS as previously described (148).  
Electrophoretic Mobility Shift Assay (EMSA)
Nuclear extracts were prepared using standard methodologies, quick frozen in
liquid nitrogen, and stored at -80° C.  For EMSA, 5 µg of nuclear protein was incubated
with [32P]-endlabeled NF-κB consensus oligonucleotide for 1 h.  End-labeling of
oligonucleotides was performed with T4 polynucleotide kinase and γ[32P] ATP.  Binding
reactions were performed in 0.25× HEGDK (25 mM HEPES pH 7.6, 1.5 mM EDTA,
10% glycerol, 1 mM DTT, 0.5 M KCl) buffer supplemented with 1 mM DTT, 20 µg
BSA, and 50 ng poly-dIdC.  After addition of loading dyes, reactions were
electrophoresed on 7% non-denaturing polyacrylamide gels at 25 mA in 0.5× TBE
(0.045 M Tris, 0.045 M Boric acid, 0.001 M EDTA).  Gels were dried and exposed to
Kodak X-OMAT film with an intensifying screen for autoradiography at -80°C for 48 h.
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SDS-PAGE and Western Blotting
Subconfluent cultures were rinsed with PBS and scraped.  The pellet was
resuspended with RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1% NP-40, 10%
sodium deoxycholate, 1 mg/ml leupeptin, 1 mg/ml aprotinin, 1 mg/ml pepstatin) and
stored at -20°C.  Three-10 µg of protein were diluted in sample buffer, boiled for 5 min,
and loaded into a 7% denaturing polyacrylamide gel.  Electrophoresis proceeded at 18-
22 mA until tracking dyes reached the bottom.  The gels were equilibrated in transfer
buffer for 5 min, and then transferred to nitrocellulose membranes for 9 h at 20V at 4°C.
Membranes were blocked in 5% milk in TBS (0.1 MTris pH 7.5, 0.15 MNaCl) with
0.1% Tween (TTBS) for 18 h, then probed overnight with a 1:1000 dilution of rabbit
primary antibody.  After 6 × 5 min washes in TTBS, membranes were incubated for 4 h
with a 1:25000 dilution of goat anti-rabbit IgG conjugated to horseradish peroxidase
(HRP).  Following another series of washes, membranes were incubated for 5 min in a
1:2 dilution of chemiluminescent substrate, and then visualized for 30 sec to 2 min on
Kodak X-OMAT film.
Immunoprecipitation
Twenty-five µg of protein was incubated overnight at 4°C with 1 µg of antibody
against IKK.  Fifty µl of a 50% slurry in TE (10 mmol/L Tris, 1 mmol/L EDTA pH 8.0)
of Protein A sepharose was added to each immunoprecipitation reaction, and agitated for
4 h at room temperature.  The sepharose beads were pelleted, and washed three times
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with TBS.  Pellets were resuspended in Laemmli sample buffer, and boiled for 5 min.
After sepharose beads were pelleted, 10 µl of supernatant was loaded for SDS-PAGE.
Synthetic NF-κB Oligonucleotides
Following examination of published sequences for mouse c-Ha-ras promoter, rat
osteopontin promoter, and rat matrix metalloproteinase-9, oligonucleotides
corresponding to NF-κB binding domains in these promoters were synthesized.  The
Genbank accession numbers and sequences used for each are described in Table I.
Underlined sequences represent NF-κB binding motifs.
TABLE I
NF-κB binding sequences used in this study
DNA sequences used for EMSA are shown.  Synthetic complementary
oligonucleotides were synthesized, annealed, and used for assessment of NF-κB binding.
Gene promoter Sequence
Mouse H-ras
(AF268311)
5’ GGG  GGT  GGG  GTC  CTC  CCT  TTT 3’
3’ CCC  CCA  CCC  CAG  GAG  GGA  AAA 5’
Rat OPN
(AF017274)
5’ GAT  TTG  TGG  AAT  TTC  CCT  GCA 3’
3’ CTA  AAC  ACC  TTA  AAG  GGA  CGT 5’
Rat MMP-9
(AJ428366)
5’ GGG  GTT  AGG  GGG  TTC  CCC  GTG 3’
3’ CCC  CAA  TCC  CCC  AAG  GGG  CAC 5’
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Real Time RT-PCR
A number of genes were selected for examination by Real Time RT-PCR, on the
basis of importance to the phenotype and/or putative regulation by NF-κB.  These genes
included MMP-2, MMP-9, cyclin D1, and osteopontin.  mRNA levels for p65 and
p50/p105 were also assessed.  β-actin was included as a control.  Primers were designed
using the Primer Express program by Applied Biosystems (Table II).  
TABLE II
Real-Time RT-PCR primers used in this study
Primers designed using Applied Biosystems’ Primer Express program for genes
of interest are listed.  
Gene Orientation Sequence
Rat MMP-2
(NM_031054)
Forward
Reverse
5’ CCCATGAAGCCTTGTTTACCA 3’
5’ TGGAAGCGGAACGGAAACT 3’
Rat MMP-9
(NM_031055)
Forward
Reverse
5’ GAGGATCCGCAGTCCAAGAA 3’
5’ GCACCGTCTGGCCTGTGTA 3’
Rat Cyclin D1
(NM_171992)
Forward
Reverse
5’ TCTGCGAGCCATGCTTAAGA 3’
5’ CCTCTGCACGCACTTGAAGTAA 3’
Rat Osteopontin
(AB001382)
Forward
Reverse
5’ TGAGACTGGCAGTGGTTTGC 3’
5’ CCACTTTCACCGGGAGACA 3’
Rat p65
(XM_219514)
Forward
Reverse
5’ GAAGAGTCCTTTCAATGGACCAA 3’
5’ GGGAAGGCACAGCAATACGT 3’
Rat p50/p105
(L26267)
Forward
Reverse
5’ CCAACGCCCTCTTCGACTAC 3’
5’ CGGTGAGATGGCGCTGTAC 3’
Rat β-actin
(NM_031144)
Forward
Reverse
5’ TCTGTGTGGATTGGTGGCTCTA 3’
5’ CTGCTTGCTGATCCACATCTG 3’
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Briefly, 1 µg of DNase-treated RNA was incubated with reverse transcriptase, a mix of
deoxynucleotides, and oligo dT to a total volume of 12 µL, and allowed to incubate
overnight at 14°C.  2 µL of the RT reaction was incubated with SYBR Green Master
Mix from Applied Biosystems, forward and reverse primers, and water to a final volume
of 25 µL.  Real Time PCR was performed in a Biorad iCycler, and assessed using the
∆CT method (154), using β-actin as a control.  Quality of primers was assessed by melt
curve to assure that only one PCR product was generated.  
Generation of Osteopontin Promoter Constructs
The full-length promoter of rat osteopontin was obtained from Dr. Amy Ridall of
the University of Texas Health Science Center in Houston, TX.  2094 base pairs of the
promoter was ligated into pGL2-basic using the NheI and XhoI restrictions sites in the
multicloning site.  This construct was dubbed 2094 rOPNpr.  Sequential deletions were
generated by Dr. Amy Ridall, which began at 1157 (1157 rOPNpr), 672 (672 rOPNpr),
and 127 (127 rOPNpr).
Computerized examination of 2094 rOPNpr by MatInspector v2.2 (available at
www.generegulation.de) revealed the presence of a number of transcription factor
binding sites, including vitamin D response element (VDRE), AP-1, NF-κB, and USF1.
Site-directed mutagenesis of these sites was performed using Stratagene’s QuikChange
kit.  Mutagenic oligos were designed according to Stratagene’s guidelines, and incubated
with 2094 rOPNpr as a template.  High fidelity PCR followed, and then digestion of the
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original template with DpnI endonuclease, which preferentially cleaves methylated
DNA.  Several clones were sequenced for verification of mutation of the targeted sites.
A summary of these mutations is presented below in Table III.  The transcription factor
binding site is underlined.  Mutated bases are in lower case.  
TABLE III
Site-directed mutagenesis of osteopontin promoter constructs used in this study
Transcription factor binding sites identified by computerized examination were
mutated using Stratagene’s QuikChange Site-Directed Mutagenesis kit.  These mutants
are listed below.  Binding sites are underlined, and mutated bases are denoted by
lowercase.  
Binding site Sequence
VDRE Original
Mutated
5’ CCTGGAAGGGTCATATGGTTCAGCTCCGAGG  3’
5’ CCTGGAAtcGTtcTATGGaTCtGCTCCGAGG  3’
AP-1 Original
Mutated
5’ TCGTGTTGAGTCATTCCTGTGGGC 3’
5’ TCGTGTTacaTCATTCCTGTGGGC 3’
NF-κB Original
Mutated
5’ AGGATTTGTGGAATTTCCCTGCACAGC 3’
5’ AGGATTTGaaGAATaaCaCTGCACAGC 3’
USF1 Original
Mutated
5’ AAACAAACTCATGTGGGTGTCGTGCTT 3’
5’ AAACAAACTCAaaTGGGTGTCGTGCTT 3’
Control and allylamine cells were seeded at 4 × 104 cells per well in a 12-well
plate.  The cultures were allowed to recover for 8 h and then co-transfected with a
luciferase construct and a β-gal-expressing plasmid at a ratio of 1.5 µg luciferase vector
to 1.0 µg β-gal.  These plasmids were mixed at a ratio of 6 µl to 1 µg DNA in serum-free
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medium 199.  This mixture was incubated with the control and allylamine cultures for 36
h.  The wells were then rinsed with PBS, and harvested using the lysis buffer included in
Tropix’s Galacto-Light Reporter Assay Kit (Foster City, CA).  These lysates were frozen
and then thawed.  
Twenty-five µL of the reporter lysates was pipetted into two 96-well plates.  One
set of lysates was injected with 80 µL of a luciferin working solution to assess the
luminesence generated.  Luminescence was assessed using BMG’s Fluostar OPTIMA
plate reader.  Another set of lysates was mixed with 70 µL of Tropix’s β-gal reagent,
allowed to incubate for 1 and then injected with 100 µL of the accelerator solution
immediately prior to measurement in the OPTIMA plate reader.  
Statistics
Real Time RT-PCR data was analyzed using the comparative ∆CT method as
previously described (154).  All other statistical relationships were examined by
ANOVA and Fisher’s least significant difference, unless otherwise noted.  Statistical
significance was assigned at the P < 0.05 level.   
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RESULTS
Dysregulation of NF-κB Activity 
Repeated cycles of oxidative chemical injury induce proliferative (i.e.
atherogenic) vSMC phenotypes characterized by enhanced secretion and deposition of
matrix proteins and modulation of integrin-coupled NF-κB signaling (148).  Because
nuclear translocation of NF-κB is dependent upon degradation of IκB proteins (86),
experiments were first conducted to evaluate steady state protein levels of IκBα and
IκBβ across a full synchronization and cell cycle transition regimen in control and
allylamine cells.  vSMCs were seeded on a plastic substrate and synchronized at G0 by
mitogen restriction over a 72-h period as described (148), and released into growth by
addition of 10% serum.  The relative abundance of IκΒs was not affected by growth
factor deprivation since comparable protein levels were detected in synchronized
cultures, as well as 0.5 hours after mitogen addition.  Degradation of IκBα was observed
in activated cells within 1 hr of serum stimulation (Fig. 7), a response that peaked by 2 h
and began to subside by 3 h.  Modest reductions in IκBα were observed in control
vSMCs, confirming that early activation of NF-κB by serum mitogens is a key feature of
the atherogenic phenotype.  No degradation of IκBβ was observed in either cell type at
any of the time points examined.
The degradation of IκB proteins is preceded by phosphorylation by the IκB-
kinases, IKKα and IKKβ (155).  Analysis of immunoprecipitated IKK in cells seeded on
plastic revealed a higher level of serine phosphorylation in allylamine vSMCs,
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irrespective of growth status (Fig. 8).  Two immunoreactive bands were detected,
indicating recognition of both IKKα and IKKβ isoforms.  Isoform specific analysis
revealed that phosphorylation of these kinases was increased in atherogenic vSMCs, and
that phosphorylation was dependent upon the degree of mitogenic stimulation.  
Fig. 7:  IκBα and IκBβ protein levels in control and allylamine vSMC cultures over
a timecourse of synchronizaton and mitogenic stimulation.  Cells were seeded at
equivalent densities and serum restricted for 72 h to synchronize in G0, and then released
into growth by addition of 10% fetal bovine serum.  Crude protein extracts were
harvested at various times after addition of complete medium.  Protein extracts were
electrophoresed, electroblotted onto nitrocellulose, and probed for each IκB.  Similar
results were observed in 3 separate experiments.  C= control, A = allylamine.
Next, experiments were conducted to examine a time course of NF-κB binding
activity to a consensus sequence in quiescent vSMC cultures following mitogenic
stimulation.  Cells were synchronized as described (150), and stimulated into growth
with 10% serum for up to 5 h. The profile of NF-κB binding activity in allylamine
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vSMCs was different from control counterparts, with 3 distinct complexes detected at
different times (Fig. 8).  Constitutive NF-κΒ binding activity was enhanced in
atherogenic vSMCs relative to controls.  This finding is consistent with observed
increases NF-κB activation within the medial wall of aortas isolated from allylamine-
treated animals (Partridge et al, unpublished data, 2003).  Mitogenic stimulation induced
protein binding as early as 0.5 hr in both cell types, but the predominance of individual
complexes over time was phenotype-specific (Fig. 9).  These findings suggest that
different species of NF-κΒ transcription factor may be active in vSMCs expressing
atherogenic phenotypes.  Pursuant to these findings, nuclear proteins were incubated
with antibodies to each of the Rel proteins before addition of end-labeled NF-κB
sequences in order to identify proteins present within specific complexes.  None of these
experiments revealed the composition of the DNA binding complexes observed.  These
results may be explained by the antibodies used, or as a consequence of the nature of the
complexes assembled on the DNA sequence.
Collagen I restricts the proliferative advantage of atherogenic vSMCs, while
seeding on plastic, fibronectin, and laminin promotes enhanced mitogenic activity (148).
To examine the influence of matrix on profiles of NF-κB binding activity, vSMCs were
seeded on different matrices and processed for nuclear protein binding analysis.  The
matrix influenced the relative abundance of individual complexes detected (Fig. 10) 
NF-κB binding activity was higher after mitogenic release in allylamine vSMCs
compared to control cells on plastic, fibronectin, or laminin, but not collagen I (compare
lanes 1 and 7, and lanes 4 and 10).  Complexes labeled C1 and C2 were prominent on all
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Fig. 8:  Total serine phosphorylation of immunoprecipitated IKKα and IKKβ in
control and allylamine vSMC cultures.  Immunoprecipitated IKKα/β was
electrophoresed and transferred onto two nitrocellulose membranes and blocked
overnight in 5% milk.  One membrane was probed for IKKα/β, and the other for
phosphoserine, followed by incubation with a horseradish peroxidase (HRP)-labeled
secondary.  Membranes were then incubated with chemiluminescent substrate and
visualized using the Kodak Image Station.  Densitometry was performed using Kodak
1D Image Software.  C (?) = control, A (?)= allylamine.
matrices, but the intensity of C3 was matrix-specific (compare lanes 1 and 4 for
fibronectin versus laminin).  On permissive substrates, increased NF-κB binding activity
in allylamine cells was evident after mitogenic release.  Binding of C2 and C3 was
stronger in allylamine cells than controls seeded on plastic, while enhancement of
activity was evident for all 3 complexes in cells seeded on fibronectin and laminin.
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Fig. 9:  NF-κB DNA binding activity in control and allylamine cells over a
timecourse of synchronization and mitogenic stimulation.  Cells were seeded at
equivalent densities on plastic tissue culture dissues.  Nuclear extracts were collected at
multiple timepoints as noted.  EMSAs were performed using end-labeled NF-κB
consensus oligonucleotides as a probe.  Arrows denote major NF-κB binding complexes
detected.  Similar results were seen in 2 independent experiments.  C# represents
individual complexes.
Though the intensity of all complexes was higher in growth-arrested allylamine cells
seeded on collagen I, this enhancement was abolished upon addition of serum mitogens,
suggesting that the response of allylamine cells seeded on a collagen I matrix to
mitogenic stimulation is deficient.  Competition with excess unlabeled oligonucleotide
(lanes 2, 5, 8 and 11) and non-specific oligonucleotide probe (lanes 3, 6, 9, and 12)
demonstrated that all complexes were specific to the NF-κB sequence.  The
enhancement of NF-κB binding activity in allylamine cells was most evident on
fibronectin (compare lanes 4 and 10), consistent with the notion that fibronectin is a
highly permissive substrate for activated vSMCs.  Thus, matrix-dependent effects in NF-
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κB binding activity correlate with patterns of proliferative activity in control and
allylamine vSMCs (148).
Fig. 10:  NF-κB DNA binding profiles in control and allylamine vSMCs seeded on
plastic, collagen I, fibronectin, and laminin.  Nuclear extracts were collected after 72 h
of synchronization (Sync), or following 2 h of mitogenic stimulation with 10% FBS
(Rlsd).  EMSAs were performed using end-labeled NF-κB consensus oligonucleotide as
a probe without competitor (lanes 2. 5, 8, and 11), 100-fold excess unlabeled NF-κB
oligo as a specific competitor (lanes 3, 6, 9, and 12), or 50 ng poly dIdC as a non-
specific competitor (lanes 4, 7, 10, and 13).  End-labeled probe without nuclear protein
was run as a control (fp).  Arrows denote major NF-κB binding complexes observed.
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Fig. 11:  Expression of Rel proteins in control and allylamine cells seeded on plastic,
collagen I, fibronectin, and laminin.  Protein extracts from cells at 80% confluence
were electrophoresed in a 7% denaturing polyacrylamide gel, transferred onto
nitrocellulose and blocked overnight in 5% milk in TBS with 0.1% Tween.  Membranes
were probed overnight, followed by incubation with horseradish peroxidase-labeled
secondary antibody for 4 h, and then incubated with 1:2 chemiluminescent substrate
:TTBs for 5 min, followed by visualization through autoradiography.  Similar
experiments were seen in 2 experiments.  C = control, A = allylamine.
Aberrant NF-κB activity in allylamine cells may be accounted for by differences
in Rel protein expression.  To evaluate this possibility, control and oxidant-activated
vSMCs were seeded on plastic, collagen I, fibronectin, and laminin and total cellular
protein extracted and analyzed by SDS-PAGE and Western immunoblotting (Fig. 11).
The abundance of RelA/p65 was influenced by matrix and cellular phenotype, with
reductions in band intensity observed in allylamine cells seeded on plastic, fibronectin or
laminin, but not collagen I.  A second immunoreactive band at approximately 45 kDa
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was detected exclusively in allylamine vSMCs on all matrices, with signal intensity
being most prominent on plastic.  The levels of RelB protein were slightly lower in cells
of the allylamine phenotype seeded on all substrates, and, as with p65, this reduction was
most pronounced on plastic.  c-Rel and p52 expression increased in allylamine cells
seeded on plastic or collagen I, but decreased on fibronectin or laminin.  In contrast, p50
expression was elevated in activated cells seeded on plastic or collagen I, but remained
unchanged when cells were seeded on fibronectin or laminin.  Analysis of p65 and p105
(the precursor of p50) by Real Time RT-PCR suggests that any change in protein levels
in allylamine cells is not a function of increased transcription, either in intact aortas
(Figs. 12 and 13), or in cultured cells (Fig. 14).  
Fig. 12:  RelA/p65 mRNA expression in control- and allylamine-treated
aortas.  mRNA was isolated from the aortae of treated animals, and processed for Real
Time RT-PCR for quantitation of p65 mRNA levels.  Animals A12 and A15 were
treated with water (control), and A26 and A33 were treated with allylamine. ? =
control, ? = allylamine.
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Next, Rel protein levels were examined in nuclear extracts to determine if
changes in cytoplasmic levels are conveyed to the nucleus.  Nuclear expression of
RelA/p65, c-Rel, and p50 was not influenced by mitogenic conditions or cellular
phenotype on a plastic substrate (Fig. 15).  In contrast, nuclear RelB levels were
decreased, while nuclear levels of p52 were increased in allylamine vSMCs irrespective
of mitogenic stimulation.  The 45 kDa immunoreactive band detected in RelA/p65
immunoblots was not detected in the nuclear compartment under any of the conditions
examined.  Thus, differences in total and nuclear Rel protein levels across cellular
phenotype under different mitogenic conditions suggest that activation of a different
subset of NF-κΒ dimers may predominate in allylamine cells.  
Fig. 13:  p50 (p105) mRNA expression in control- and allylamine-treated aortas.
mRNA was isolated from the aortae of treated animals, and processed for Real Time RT-
PCR for quantitation of p50 mRNA levels.  Animals A12 and A15 were treated with ater
(control), and A26 and A33 were treated with allylamine. . ? = control, ? = allylamine.
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Fig. 14:  Expression levels of p65 and p50 (p105) in control and allylamine cells.
mRNA was isolated from subconfluent cultures of control and allylamine cultures, and
processed for Real Time RT-PCR. . ? = control, ? = allylamine.
Fig. 15:  Expression of Rel protein in nuclear extracts from control and allylamine
cells under various growth stimulatory conditions.  Cells were seeded on plastic
culture dishes and allowed to reach 80% confluence.  Protein extracts were
electrophoresed, transferred onto nitrocellulose, and blocked overnight in 5% milk in
TBS with 0.1% Tween.  The membrane was probed for each protein, followed by
incubation with a horseradish peroxidase (HRP) labeled secondary antibody for 1.5
hours.  Membranes were incubated with 1:2 chemiluminescent substrate:TTBS for 5
minutes and visualized through autoradiography.  C = control, A = allylamine.
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Examination of nuclear Rel protein levels also suggested high constitutive
nuclear localization of NF-κB constituents, which may indicate differential activation
pathways in adherent vSMCs, as opposed to immune cells in which prototypical NF-κB
pathways have been described.
Phenotype-specific changes in the prevalence of Rel proteins may translate into
variable composition of NF-κB dimers.  Such alterations may influence the profile of
transcriptional regulation, as different dimers preferentially recognize different target
sequences (79).  To test this concept, NF-κB binding elements from four different
promoters were used to evaluate binding activity in nuclear extracts from control and d 
Fig. 16:  DNA binding activity to a panel of NF-κB binding sequences in control and
allylamine vSMCs.  Nuclear extracts were subjected to EMSA against NF-κB binding
domains from several promoters (Ha-ras, rOPN, and rMMP-9), as well as a consensus
oligo (Promega).  Gels were dried, and exposed to film for 48 h at -80° C with
intensifying screen.  Arrows denote NF-κB binding complexes identified.  C = control,
A = allylamine.
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be identified, two of which were conserved across all of the NF-κB binding sequences
allylamine vSMCs seeded on plastic. Up to four major binding protein complexes coul
examined (Fig. 16).  With the exception of proteins bound to the NF-κB sequence from
the rat matrix metalloproteinase-9 promoter, band intensities were higher in nuclear
extracts from oxidant-activated vSMCs compared to controls, indicating a higher degree
of NF-κB activation.  The intensity of the two faster-mobility complexes (C3 and C4) 
Fig. 17:  Cross-competition analysis of DNA binding of nuclear proteins from
control and allylamine cells to the c-Ha-ras NF-κB element.  Nuclear proteins from
randomly cycling cultures of control and allylamine vSMCs were incubated with the
endlabeled c-Ha-ras NF-κB element.  Competitions were performed with 50X and 100X
excess unlabeled c-Ha-ras NF-κB oligonucleotide, 50X consensus NF-κB
oligonucleotide (Promega), 50X rat osteopontin NF-κB oligonucleotide (rOPN), 50X
tumor necrosis factor alpha oligonucleotide (TNF-α), and 50 ng nonspecific DNA
oligonucleotide (dIdC).  Arrows denote major NF-κB DNA binding complexes
observed.  C = control, A = allylamine.
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was sequence-specific, with strong binding observed to the Promega consensus and c-
Ha-ras sequences.  To further examine sequence-specificity of NF-κB binding within
this context, cross-competition analysis was performed to examine the composition of
complexes that bound to the c-Ha-ras promoter.  Incubation of unlabeled NF-κB
sequences for TNF-α, osteopontin, and a consensus sequence competed away binding to
the c-Ha-ras element (Fig. 17).  However, varying degrees of competition were
observed, suggesting that some complexes, especially the fastest migrating,
preferentially bind to the NF-κB element within the c-Ha-ras promoter.
Fig. 18:  Osteopontin mRNA expression in control- and allylamine-treated aortas.
mRNA was isolated from the aortae of treated animals, and processed for Real Time RT-
PCR for quantitation of osteopontin mRNA levels.  Animals A12 and A15 were treated
with water (control), and A24 and A26 were treated with allylamine. ? = control, ? =
allylamine.
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As mentioned previously, NF-κB is a driving influence on the expression of a
wide variety of genes (78).  Pursuant to observations of promoter-specific enhancements
of NF-κB binding activity in allylamine cells, examinations of RNA levels of several of
the targets were performed using Real Time RT-PCR.  Increases in ras RNA levels have
been described previously in our laboratory (150).  Real Time RT-PCR demonstrates
increased osteopontin message both in vivo (Fig. 18) and in vitro (Fig. 19).  This
observation is consistent with microarray data derived from aortic RNA samples from
control and allylamine-treated animals (Partridge et al, unpublished data 2002).
However, no such increase in MMP-9 message is observed (Fig. 20).  This finding is of
particular interest considering the lack of enhancement of NF-κB binding activity 
Fig. 19:  Expression levels of osteopontin in control and allylamine cells.  mRNA was
isolated from subconfluent cultures of control and allylamine vSMCs, and processed for
Real Time RT-PCR. ? = control, ? = allylamine.
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observed against the MMP-9 DNA sequences.  However, marked enhancements in
MMP-2 RNA levels (Fig. 21), a gene regulated by NF-κB activity, were observed (78).
Thus, the signature of NF-κB DNA binding activity is consistent with RNA message 
Fig. 20:  MMP-9 mRNA expression in control- and allylamine-treated aortas.
mRNA was isolated from the aortae of treated animals, and processed for Real Time RT-
PCR for quantitation of MMP-9 mRNA levels.  Animals A12 and A15 were treated with
water (control), and A26 and A33 were treated with allylamine. ? = control, ? =
allylamine.
levels, suggesting that promoter-specific differences in NF-κB binding to cis-acting
elements play a role in differential gene expression in control vs. allylamine cells.
Experiments with PDTC suggest a vital role for NF-κB in the proliferative advantage of
allylamine cells compared to controls.  One NF-κB target that could contribute to
enhanced proliferative capacity is cyclin D1, which is responsible for the transition from
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G1 phase to S phase. (98, 156).  Examination of cyclin D1 RNA levels in randomly
cycling cells revealed a slight increase in message in vitro (Fig. 22). No difference
Fig. 21:  MMP-2 mRNA expression in control- and allylamine-treated aortas.
mRNA was isolated from the aortae of treated animals, and processed for Real Time RT-
PCR for quantitation of MMP-2 mRNA levels.  Animals A12 and A15 were treated with
water (control), and A26 and A33 were treated with allylamine. ? = control, ? =
allylamine.
was observed in vivo (Fig. 23).  However, increased cyclin D1 protein levels were
observed in allylamine cells compared to controls (Jones et al, unpublished observations
2003).  Thus, the pathway of NF-κB-mediated dysregulation of proliferation in cultured
cells may converge through increased cyclin D1 expression.  
Osteopontin Promoter Analysis
Enhanced secretion of osteopontin is a hallmark of the allylamine phenotype.
Increased osteopontin RNA levels were observed in from treated vessels by Real Time
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RT-PCR, confirming microarray data previously generated in our laboratory (Partridge
et al, unpublished data).  To evaluate molecular mechanisms of osteopontin regulation,
luciferase constructs containing the osteopontin promoter were generated and transfected
into control and allylamine cells.
Fig. 22:  Expression levels of cyclin D1 mRNA in control and allylamine cells.
mRNA was isolated from subconfluent cultures of control and allylamine vSMCs, and
processed for Real Time RT-PCR. ? = control, ? = allylamine.  Each set represents an
independent experiment.
2094 base pairs of the rat osteopontin promoter (rOPNpr) (AF017274) were spliced into
pGL2-basic, a luciferase vector.  Deletions were generated of this full-length construct,
beginning at 1157, 672, and 129 relative to the beginning of the parent sequence to
assess the importance of distinct regions.  These deletions are summarized in Fig. 24.
The results presented in Fig. 25 show that when these promoter constructs were
transfected into control and allylamine cells, the activity of the full-length promoter
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Fig. 23:  Cyclin D1 mRNA expression in control- and allylamine-treated aortas.
mRNA was isolated from the aortae of treated animals, and processed for Real Time RT-
PCR for quantitation of cyclin D1 mRNA levels.  Animals A12 and A15 were treated
with water (control), and A24, A26, and A33 were treated with allylamine. ? = control,
? = allylamine.
was lower in allylamine cells compared to controls.  Progressive deletions caused an
increase in promoter activity in the control cells, suggesting the presence of inhibitory
elements between 2094 and 1157, and between 1157 and 672.  An increase in activity
was also observed in allylamine cells when bases from 1157 to 672 were removed,
suggesting that inhibitory elements therein are affected in both phenotypes.  The
minimal promoter, 127, displayed very low levels of activity.  Examination of the
sequences between 2094 and 1157 revealed several cis-acting elements, including a
vitamin D response element (VDRE), AP-1 binding site, NF-κB binding site, and a
upstream stimulatory factor (USF) binding site.
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Fig. 24:  Schematic representation of the rat osteopontin promoter, cis-acting
elements within the full-length promoter, and several deletions thereof.
Several cis-acting elements were identified in the osteopontin promoter using
MatInspector v2.2.  Therefore subsequent experiments were conducted to examine the
relative contributions of specific sites by mutational analysis.  Of interest were the
vitamin D response element, AP-1 binding domain, NF-κB binding domain, and a USF
binding site.  Site-directed mutagenesis was performed using the QuikChange Site
Directed Mutagenesis kit, with appropriate mutagenic oligos.  These mutations are
detailed in Fig. 26.  Disruption of any of these elements reduced luciferase activity in
control cells (Fig. 27), suggesting cooperation between these elements or possibly low-
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Fig. 25:  Osteopontin promoter activity in control and allylamine cells.  Control and
allylamine cells were seeded at equivalent densities and allowed to recover for 8 hours.
Cultures were then transfected with the rat osteopontin promoter in pGL2-basic, a
luciferase vector, or a deletion thereof (1157 rOPNpr, 672 rOPNpr, 329 rOPNpr, and
129 rOPNpr).  Also included as a control was β-galactosidase, to allow normalization of
luciferase signal. ? = control, ? = allylamine.  * indicates significant difference from
2094 rOPNpr in control, + indicates significant difference from 1157 rOPNpr in control,
# indicates significant difference from 657 rOPNpr in control (p < 0.05).
level constitutive activity that can overcome inhibitory influences on promoter activity.
Interestingly, mutation of either the NF-κB or USF1 site returned the transcriptional
activity in allylamine cells return to full-length control levels, suggesting that
osteopontin promoter activity is under negative control by NF-κB in cooperation with
USF activity.  
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Fig. 26:  Site-directed mutagenesis of the rat osteopontin promoter.  Several sites
were identified through computerized examination, and mutated using Stratagene’s
QuikChange Site-Directed Mutagenesis kit.  Alterations in each element are denoted by
a capital letter.
Since p50 and p52 contain no transactivation domain, hetero- and homodimers of
these Rel proteins can bind NF-κB binding sites to inhibit transactivation .  This
interpretation is consistent with the higher p50 and p52 levels present in allylamine cells
compared to controls (Figs. 11 and 15).  The transactivation potential of RelA/p65 can
be affected by phosphorylation, representing another level of regulation for NF-κB-
mediated responses (95, 157).  Serine phosphorylation of p65 increases its potential for 
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Fig. 27:  Osteopontin promoter activity in control and allylamine cells after site-
directed mutagenesis.  Control and allylamine cells were seeded at equivalent densities
and allowed to recover for 8 h.  Cultures were then transfected with the rat osteopontin
promoter (rOPNpr) in a luciferase vector, or a vector in which a cis-acting element has
been mutated through site-directed mutagenesis.  These mutants are denoted VDREx
rOPNPr, AP-1x rOPNpr, NF-κBx rOPNpr, USF1x rOPNpr, USF2x rOPNpr, and USF3x
rOPNpr. ? = control, ? = allylamine.  * indicates significant difference from 2094
rOPNpr in control, + indicates significant difference from VDREx rOPNpr in control, #
indicates significant difference from NF-κBx rOPNpr in control (p < 0.05).
interactions with chromatin remodeling proteins including CBP/p300, and histone
acetyltransferases (96).  Thus, phosphorylation was examined by Western
immunoblotting of immunoprecipitated p65 for phosphoserine.  Serine phosphorylation
of p65 was noticeably reduced in allylamine cells, suggesting that p65 is less effective at
transcriptional activation in allylamine cells than control cells (Fig. 28).  This finding is
relevant in light of studies suggesting that unphosphorylated p65 associates with histone
deacetylases (HDAC1 and HDAC2) which cooperate to repress the expression of NF-
κB-regulated genes (97).
Next, the importance of matrix on osteopontin promoter activity was studied by 
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Fig. 28:  Serine phosphorylation of immunoprecipitated p65/RelA in control and
allylamine vSMCs.  Immunoprecipited p65/RelA was electrophoresed on separate gels,
and electroblotted onto nitrocellulose membranes.  The membranes were blocked
overnight in 5% milk in TBS with 0.1% Tween, and then probed for 1.5 h for p65/RelA
or phosphoserine.  The membranes were incubated with a secondary antibody
conjugated to horseradish peroxidase (HRP) for 1.5 h, and then with chemiluminescent
substrate for 5 min.  The membrane was visualized with the Kodak Image Station 4400,
and densitometry performed using the Kodak 1D Image software.  C (?) = control, A
(?)= allylamine.
seeding control and allylamine cells on collagen I, fibronectin, and laminin.  These cells
were allowed to recover, before transfection with full-length osteopontin promoter in a
luciferase construct.  Interestingly, the osteopontin promoter activity was 400% of
control in allylamine cells seeded on fibronectin (Fig. 29, panel A),  suggesting that
these cells are primed for osteopontin expression when seeded on a permissive substrate. 
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The importance of matrix on NF-κB regulation of osteopontin activity was also assessed
by comparing the full length promoter to mutants seeded on these same substrates (Fig.
29, panel B).  Deletion of the NF-κB binding site increased promoter activity in
allylamine cells seeded on collagen I.  This observation is consistent with the ability of
collagen to serve as a repressive matrix for allylamine cells (148), and suggests that NF-
κB plays a role in collagen I-mediated repression of osteopontin expression.
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Fig. 29:  Activity of osteopontin promoter-luciferase constructs in control and
allylamine cells seeded on different matrices.  Control and allylamine cells were
seeded at equivalent densities on collagen I, fibronectin, and laminin, and allowed to
recover for 8 h.  Cultures were then transfected with the rat osteopontin promoter (2094
rOPNpr) in a luciferase vector (panel A), and a full length construct in which the NF-κB
site was mutated (NF-κBx rOPNpr) (panel B).  These mutants are denoted VDREx
rOPNPr, AP-1x rOPNpr, NF-κBx rOPNpr, USF1x rOPNpr, USF2x rOPNpr, and USF3x
rOPNpr. ? = control, ? = allylamine. * indicates significantly different from control, +
indicates significantly different from 2094 rOPNpr in same cell type on same seeding
matrix (p < 0.05).
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DISCUSSION AND SUMMARY
Regulation of NF-κB Activity 
Recent work in this laboratory described increased NF-κB binding activity in
allylamine vSMCs (148).  This perturbation is critical for the maintenance of activated
phenotypes, as treatment with PDTC specifically inhibited proliferation of activated
vSMCs but not controls.  These findings are consistent with emerging evidence
implicating NF-κB dysregulation in the pathogenesis of atherosclerosis (158, 159).
Giachelli’s group have reported that NF-κB is activated in atherosclerotic vSMCs, but
not uninjured vessels (160), and NF-κB has been implicated in the chronic inflammatory
response leading to hyperproliferation of vSMCs during atherogenesis (161).  Similar
increases in NF-κB activation have been observed during the course of the atherogenic
response in oxidant-injured aortic tissue (Partridge et al, unpublished data, 2003).
The present studies detail the molecular basis for dysregulation of NF-κB activity
in oxidant-activated vSMC phenotypes.  We observed enhanced degradation of IκBα in
allylamine cells, indicative of increased nuclear translocation of NF-κB.  This finding
suggests a basis for increased proliferation of activated vSMCs, as recent studies using
purified IκBα (162) or antisense p65 (163) have independently demonstrated a vital role
for NF-κB in vSMC proliferation. Not surprisingly, phosphorylation of both IKK α and
β was increased in allylamine vSMCs compared to controls.  These findings are
consistent with previous data suggesting that induction of atherogenic phenotypes by
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oxidative injury involves disruption of PI3K, PKC, and ras signaling, all upstream
activators of IKK in vSMCs (90, 91, 94).
Processes downstream of IKK activity and IκBα degradation, such as NF-κB
nuclear localization and DNA binding activity, were also perturbed in activated cells
compared to controls.  These data are indicative of disruption of NF-κB activation in
atherogenic vSMC phenotypes, in accord with the hyperproliferative state of these cells
(100).  However, the ability of allylamine vSMCs to proliferate is dependent on
extracellular matrix-related signaling, since collagen I, but not plastic, fibronectin, or
laminin inhibit their proliferative advantage (148).  
Disruption and remodeling of the vessel wall matrix is a pivotal process in
atherogenesis.  Expression of activated vSMC phenotypes requires disruption of the
basal lamina by macrophage metalloproteinases (66).  As the process of phenotypic
conversion progresses, activated vSMCs produce larger amounts of collagen I that
change the relative composition of the extracellular matrix (164).  Monomeric collagen I
becomes a large component of the matrix (28), as does fibronectin, a protein which
promotes dedifferentiation of vSMCs within the lesion (36).  Previous data have
indicated that collagen I restricts the ability of oxidant-activated cells to proliferate more
rapidly than controls, while cells seeded on plastic, fibronectin or laminin display the
allylamine phenotype (148).  Matrix-dependent increases in NF-κB binding activity are
consistent with this pattern, suggesting a link between matrix signaling and NF-κB in the
regulation of proliferative activity of allylamine vSMCs.  Mature collagen I may elicit a
reduction in proliferative activity through increased expression of cdk2 inhibitors, as
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demonstrated in arterial SMCs (32) . Repression of NF-κB activity by overexpression of
IκB in HeLa cells is associated with a similar response (165).  We have recently shown
that a collagen I matrix modulates p21 and cyclin D1 expression in allylamine vSMCs
(Jones, Wilson, and Ramos, unpublished observations, 2003), key targets of NF-κB
regulation (98, 99, 166).  The underlying mechanisms that translate the interactions
between integrins and extracellular matrix proteins to transcriptional responses remain to
be fully elucidated.  It is clear that in healthy vessels, matrix interactions serve to protect
against hyperproliferation of vSMCs.  However, in injured vessels, as the composition of
the matrix changes, so do the responses of cells within the vessel wall, especially those
involving integrin-coupled NF-κB activation and function.
The appearance of multiple complexes of varying mobility as a function of time
and substrate prompted examination of the levels of NF-κB constituent Rel proteins.
Few studies have examined mechanisms that modulate the expression of these proteins.
An Ets-family transcription factor was implicated in c-rel expression (167), and the
expression of p50/p105 is probably regulated by NF-κB itself (168).  Several matrix-
dependent alterations in total cellular Rel protein expression were noted in allylamine
vSMCs compared to control counterparts.  Changes in Rel protein levels were also noted
in nuclear extracts.  On the basis of simple stoichiometry, it is likely that altered
expression of Rel proteins leads to differences in the prevalence of NF-κB dimers
present at any given point in time (Fig. 30).  Because each dimer has a subset of DNA
domains to which binding is most favorable (79), a shift in relative Rel protein
expression levels could result in differential modulation of gene expression.  Such a shift
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in dimer prevalence has been described during B-cell differentiation, leading to altered
transcriptional activation of the immunoglobulin κ light chain (169).  Further, the
importance of dimer identity to the effect of NF-κB binding has been the focus of
several recent studies (170, 171).  The pattern and intensity of NF-κB binding activity in 
Fig. 30:  Representation of NF-κB dimers favored in allylamine cells.  Based on
relative expression levels, the assembly of these dimers is favored stoichiometrically.  
control versus allylamine vSMCs varied among the four different promoter sequences
examined, suggesting that a shift in NF-κB dimer prevalence plays a role in the
regulation of allylamine vSMC phenotypes.  As p50 and p52 protein levels are increased
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in allylamine cells, hetero- and homodimers of these two proteins may be more
prevalent.  These dimers would act more often as transcriptional repressors.
Further, high levels of constitutive NF-κB nuclear residence in both control and
allylamine cells was noted, though these increases did not translate into increased DNA
binding activity.  These observations suggest that NF-κB can be regulated at the level of
binding to DNA, consistent with observations that cytosolic modifications of Rel
proteins and subsequent changes in DNA binding can affect the ability of NF-κB to
regulate gene expression (172, 173).
Examination of NF-κB-regulated target genes revealed a pattern consistent with
these observations.  Osteopontin mRNA levels are increased in response to allylamine
injury both in vivo and in vitro, consistent with several studies which demonstrate
increases in osteopontin in atherosclerosis (40, 174).  However, no such enhancement
was noted for MMP-9 mRNA levels.  This finding is in contrast to studies that suggest
that NF-κB is responsible for increases in MMP-9 expression (175), in response to
inflammatory cytokines IL-1α in vSMCs.   This difference in response may be attributed
to different signaling pathways activated in these separate systems.  In any case, patterns
of NF-κB binding to promoter sequences correlate with increased mRNA expression in
this oxidant-injury model of atherosclerosis. 
As experiments with PDTC have demonstrated, NF-κB activity is critical to
enhanced proliferative capacity in allylamine cells.  One NF-κB target that could
account for this phenomenon is cyclin D1 (98, 156).  Though only slight increases in
mRNA levels were observed in vitro, cyclin D1 protein was increased in allylamine cells
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(Jones Wilson and Ramos, in preparation 2003).  Given that matrix-dependent patterns
of NF-κB enhancement coincide with the proliferative advantage of oxidant-activated
vSMCs, and inhibitors of NF-κB abolish the proliferative potential of allylamine vSMCs
(148), we conclude that NF-κB participates in matrix-dependent regulation of the
allylamine vSMC phenotype following oxidative injury.  
Osteopontin Promoter Activity in Control and Allylamine Cells
Several observations both in the allylamine model and other models suggest that
osteopontin is a critical modulator of atherosclerosis (148, 176, 177).  Increased
production of osteopontin after injury has been described in balloon angioplasty models
of atherosclerosis (40, 174), as well as in this oxidant injury model of atherosclerosis
(149).
The findings of the present study demonstrate that alterations in mRNA level in
allylamine cells are not mediated at the transcriptional level.  This conclusion is based
upon the finding that promoter activity in allylamine cells was consistently lower than in
control cells irrespective of the length of the promoter, or the deletion of putative
activator/repressor sequences.  Progressive deletion analysis uncovered strong repressor
sequences within the promoter in vascular smooth muscle cells irrespective of growth
phenotype. The downstream elements responsible for these patterns of activity remain to
be established.  
Osteopontin is an acute response gene involved in survival and proliferation (39).
As such, immediate activation of the gene in response to stress likely involves
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transcriptional activation (178).  In contrast, the allylamine phenotype results from long-
term adaptation to repeated cycles of oxidative injury and expression of new steady
states involving differential regulation of stress response genes.  Thus, a lack of
transcriptional enhancement of the osteopontin gene in allylamine cells seeded on non-
permissive substrates is to be expected.  Because the allylamine phenotype is highly
dependent on matrix production and deposition, transcriptional enhancement of
atherogenic genes follows similar patterns.   
Surprisingly, few studies have focused on transcription factors responsible for
increases in osteopontin production in atherosclerosis.  Several studies have suggested
the importance of upstream stimulatory factors (USF1) in injury-induced osteopontin
expression (179), and in response to diabetic hyperglycemia (180).  AP-1 has also been
implicated (180), perhaps as a result of increased ERK1/ERK2 activity (177).  Computer
assisted analysis of the rat osteopontin promoter revealed binding sites for both of these
elements, as well as for the vitamin D receptor (VDRE) and NF-κB.  Analysis of
promoters in which these sites were mutated yielded a complex picture which suggests a
role for NF-κB in repression of promoter activity in allylamine cells seeded on non-
permissive substrates.  Also, data generated after disruption of the USF1 site suggests a
degree of cooperation between this factor and NF-κB, as mutation of either site returns
promoter activity in allylamine cells back to control levels.  The ability of NF-κB to
repress gene transcription as a function of p50 and p52 hetero- and homodimers has been
the subject of several recent studies (83, 181), as has the potential for USF1 binding to
repress the transcription of CYP1A1 (182) and plasminogen activator inhibitor-1 (183). 
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Indeed, a study of NF-κB binding sites suggests a high affinity of repressive NF-κB
dimers for the osteopontin promoter sequence (81).   Cooperativity between these two
transcription factors in binding to nucleosome cores has also been recently described
(184).  Thus, cooperative binding of NF-κB and USF1 to the promoter of osteopontin
may help to effect repression of activity in allylamine cells.  However, in control vSMC
populations, it is apparent that all of the examined sites are responsible for
transcriptional increases to varying degrees, suggesting that recruitment of NF-κB
complexes in control and allylamine cells is altered.  This interpretation is consistent
with differential patterns of Rel protein expression between these two cell types.
Differential post-translational modifications of Rel proteins may also participate
in altered DNA binding activity and/or transactivation potential (96, 157).  This
phosphorylation event has been attributed to several different kinases, including casein
kinase II (185, 186), p38 MAPK (187), IKKα (188), PKA (96), PKC (189),  and
PI3K/Akt (95, 190).  In our system, immunoprecipitated p65 is less phosphorylated in
allylamine cells than in control cells, suggesting that NF-κB dimers which contain this
Rel protein would be less likely to transactivate, due to their inability to engage
chromatin remodeling machinery (96) and association with histone deacetylases which
would inhibit accessibility to DNA binding sites (97).
Signaling through integrin receptors bound to fibronectin increases osteopontin
promoter activity in allylamine cells, while no such enhancement is observed in
populations seeded on collagen I or laminin.  The ability of fibronectin to induce
dedifferentiation of vSMCs has been well-documented (191-193), as well as its ability to
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induce expression of osteopontin in cultured vSMCs (194).  Regulation of osteopontin
expression in cells seeded on fibronectin clearly does not involve NF-κB to a large
degree, though this pattern is subject to substrate/matrix regulation on plastic.  In that
regard, fibronectin may induce a different profile of transcriptional regulators that
influence the activity of this promoter.  It should be noted, however, that repression of
activity on collagen I may be partially accomplished through the NF-κB element.  This
interpretation is consistent with a recent study showing that collagen I activates NF-κB-
regulated transcriptional programs (195).
  
Summary
Dysregulated NF-κB plays a role in a number of diseases, including
atherosclerosis, arthritis, cancer, diabetes, AIDS, and stroke (196).  In most of these
disease states, inflammation is a key component in pathologic progression.  In
atherosclerosis, activated NF-κB has been described in vivo (160), and as a critical
modulator of vSMC proliferation and phenotypic conversion in vitro (161).  In the
context of atherogenesis, dysregulated NF-κB may exacerbate the condition by
upregulating adhesion molecules VCAM-1 and ICAM-1 (78), inflammatory cytokines
including TNF-α, IL-6 (197) and IL-1β, matrix metalloproteinases 1, 3, and 9 (198)
(175), protective factors such as inhibitors of apoptosis (IAPs), Bcl-XL, and c-Myc
(199), and cell cycle molecules such as cyclin D1 (98, 99, 156) and cyclin-dependent
kinase inhibitor p21Waf/Cip1 (166).  No specific NF-κB target has yet been identified that
encompasses its role in the atherosclerotic disease process.  Most likely, the importance
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of NF-κB in the atherosclerotic response lies in the activation of a subset of genes, and
repression of others, as suggested by Tian and coworkers (200).  One possibility in this 
Fig. 31:  Signaling pathways involved in regulation of the allylamine phenotype.
Altered MAPK, PKC and PI3K mediated signaling leads to enhanced activation of AP-1
and NF-κB.  AP-1 may enhance the production of genes important to vSMC
proliferation, while the action of NF-κB protects the cell from apoptosis.
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model is that NF-κB functions to repress apoptosis in atherogenic vSMC phenotypes
(198, 199), while AP-1, the activity of which is also increased in allylamine cells (147),
mediates enhanced proliferative capacity (Fig. 31) (76).  Indeed, the apparent
degradation of RelA/p65 could be a result of abortive apoptosis cascades (201-204) as
seen in Alzheimer’s disease, a related condition (205).  Our previously described
increases in MAPK activity (Jones, Wilson, and Ramos, submitted 2003) and AP-1
binding activity (148) are consistent with this model of regulation.  The interplay
between these and other transcription factors in regulation of the atherosclerotic vSMC
phenotype will doubtless continue to be the focus of studies in the future.
As noted above, osteopontin is expressed in atherosclerotic lesions in vivo (40),
and in response to injury in vitro (177).  Recent studies that employed transgenic mouse
models of osteopontin overexpression indicate that this cytokine is necessary but not
sufficient to induce neointimal thickening in response to injury (176, 206).  Further,
osteopontin transgenic mice develop lesions more quickly in response to high cholesterol
(207).  A recent study by Matsui in which male and female osteopontin knockout mice
were compared suggests a gender-related difference in the role of osteopontin in
atherosclerosis (208).  The work of Parrish and Ramos suggest that perhaps cleavage of
osteopontin, which generates a biologically active 36 kDa fragment, is a key facet of its
role in atherosclerosis (149).  
The molecular basis of osteopontin overexpression in atherosclerotic plaques
remains elusive.  In other contexts, ras (209), ERK1/ERK2 (177), PKC (210), and
transcription factors USF1 (179) and AP-1 (180) have been implicated in osteopontin
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expression.  In our model of oxidant-induced atherosclerosis, examination of promoter
activity suggests a matrix-dependent NF-κB suppressive influence on osteopontin
expression, perhaps in cooperation with USF1.  In contrast, the VDRE and AP-1
elements act as enhancers of expression in uninjured cell populations.  Thus, as
increased osteopontin mRNA levels have been described both in the present studies and
in several previous reports (149, 211), the possibility of regulated mRNA stability must
be considered.  Also, studies that examine mutation of multiple elements within the
osteopontin promoter would shed more light on the repressive and stimulatory influences
at play in this system.
In the present studies, the details of dysregulation of NF-κB pathways have been
investigated.  Evidence has been presented that altered signaling, activation, and
composition of NF-κB dimers leads to differential DNA binding and regulatory activity.
These changes lead to repression of osteopontin promoter activity and stimulation of
other target genes.  Thus, altered prevalence of NF-κB dimers results in altered profiles
of NF-κB-dependent gene regulation that play a role in maintenance of atherosclerotic
vSMC phenotypes induced by oxidant injury. 
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